Calprotectin in bile: A disease severity marker in patients with primary sclerosing cholangitis

Journal of Clinical Gastroenterology

Volumn 48, Issue 10, 2014, Pages 866-869

  Voigtländer, Torsten ^a   Wlecke, Jenny ^a   Negm, Ahmed A ^a   Lenzen, Henrike ^a   Manns, Michael P ^a   Lankisch, Tim O ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Bile; Calprotectin; Cholangiocarcinoma; Disease activity; Primary sclerosing cholangitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALGRANULIN; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE; BILE DUCT CARCINOMA; BILE DUCT STONE; BILIRUBIN BLOOD LEVEL; CANCER DIAGNOSIS; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; MAYO RISK SCORE; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PROTEIN BLOOD LEVEL; SCORING SYSTEM; BILE DUCT NEOPLASMS; BLOOD; CHEMISTRY; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; CHOLELITHIASIS; COMPARATIVE STUDY; COMPLICATION; CROSS-SECTIONAL STUDY; EVALUATION STUDY; INTRAHEPATIC BILE DUCT; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; BILE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; BIOLOGICAL MARKERS; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; CHOLELITHIASIS; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX;

EID: 84916209573     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/mcg.0000000000000042     Document Type: Article

References (29)

1. Weismü ller TJ, Lankisch TO. Medical and endoscopic therapy of primary sclerosing cholangitis. Best Pract Res Clin Gastroenterol. 2011;25: 741-752.
2. Trauner M, Halilbasic E, Baghdasaryan A, et al. Primary sclerosing cholangitis: New approaches to diagnosis, surveillance and treatment. Dig Dis. 2012;30(suppl 1): 39-47.
3. Rupp C, Mummelthei A, Sauer P, et al. Non-IBD immunological diseases are a risk factor for reduced survival in PSC. Liver Int. 2013;33: 86-93.
4. Yamamoto T, Uki K, Takeuchi K, et al. Early gallbladder carcinoma associated with primary sclerosing cholangitis and ulcerative colitis. J Gastroenterol. 2003;38: 704-706.
5. Boberg KM, Lind GE. Primary sclerosing cholangitis and malignancy. Best Pract Res Clin Gastroenterol. 2011;25: 753-764.
6. de Valle MB, Bjö rnsson E, Lindkvist B. Mortality and cancer risk related to primary sclerosing cholangitis in a Swedish population-based cohort. Liver Int. 2012;32: 441-448.
7. D'Haens G, Ferrante M, Vermeire S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18: 2218-2224.
8. Schoepfer AM, Beglinger C, Straumann A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013;19: 332-341.
9. Németh J, Stein I, Haag D, et al. S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology. 2009;50: 1251-1262.
10. Gebhardt C, Németh J, Angel P, et al. S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol. 2006;72: 1622-1631.
11. Ehrchen JM, Sunderkö tter C, Foell D, et al. The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. J Leukoc Biol. 2009;86: 557-566.
12. Grebhardt S, Veltkamp C, Strö bel P, et al. Hypoxia and HIF-1 increase S100A8 and S100A9 expression in prostate cancer. Int J Cancer. 2012;131: 2785-2794.
13. Kim H-A, An J-M, Nam J-Y, et al. Serum S100A8/A9, but not follistatin-like protein 1 and interleukin 18, may be a useful biomarker of disease activity in adult-onset Still's disease. J Rheumatol. 2012;39: 1399-1406.
14. Jung S-Y, Park Y-B, Ha Y-J, et al. Serum calprotectin as a marker for disease activity and severity in adult-onset Still's disease. J Rheumatol. 2010;37: 1029-1034.
15. Reinhard L, Rupp C, Riedel H-D, et al. S100A9 is a biliary protein marker of disease activity in primary sclerosing cholangitis. PLoS One. 2012;7: E29821.
16. Holzinger D, Frosch M, Kastrup A, et al. The Toll-like receptor 4 agonist MRP8/14 protein complex is a sensitive indicator for disease activity and predicts relapses in systemiconset juvenile idiopathic arthritis. Ann Rheum Dis. 2012; 71: 974-980.
17. Pezzilli R, Barassi A, Morselli-Labate AM, et al. Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: A possible link between pancreatic insufficiency and intestinal inflammation. J Gastroenterol. 2007; 42: 754-760.
18. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc. 2000;75: 688-694.
19. Negm AA, Schott A, Vonberg R-P, et al. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. Gastrointest Endosc. 2010;72: 284-291.
20. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: A review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol. 2013;7: 103-114.
21. Singh S, Talwalkar JA. Primary Sclerosing Cholangitis-Diagnosis, Prognosis and Management. Clin Gastroenterology Hepatol. 2013;11: 898-907.
22. Bergquist A, Ekbom A, Olsson R, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol. 2002;36: 321-327.
23. Hirschfield GM, Heathcote EJ, Gershwin ME. Pathogenesis of cholestatic liver disease and therapeutic approaches. Gastroenterology. 2010;139: 1481-1496.
24. Syal G, Fausther M, Dranoff JA. Advances in cholangiocyte immunobiology. Am J Physiol Gastrointest Liver Physiol. 2012; 303: G1077-G1086.
25. Lankisch TO, Metzger J, Negm AA, et al. Bile proteomic profiles differentiate cholangiocarcinoma from primary sclerosing cholangitis and choledocholithiasis. Hepatology. 2011;53: 875-884.
26. Al Mamari S, Djordjevic J, Halliday JS, et al. Improvement of serum alkaline phosphatase to 1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis. J Hepatol. 2013; 58: 329-334.
27. Lindström L, Hultcrantz R, Boberg KM, et al. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2013;11: 841-846.
28. Yong H-Y, Moon A. Roles of calcium-binding proteins, S100A8 and S100A9, in invasive phenotype of human gastric cancer cells. Arch Pharm Res. 2007;30: 75-81.
29. Arai K, Takano S, Teratani T, et al. S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets. 2008;8: 243-252.